Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Alpha Tau Medical Ltd ( (DRTS) ).
Alpha Tau Medical Ltd., developer of the Alpha DaRT intratumoral alpha-radiation cancer therapy, reported on May 5, 2026 that its abstract on combining Alpha DaRT with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma has been selected for a podium presentation at the AHNS 12th International Conference on Head and Neck Cancer in Boston. The study, conducted at Hadassah Medical Center in Jerusalem, builds on prior monotherapy data and underscores Alpha Tau’s strategic shift toward combination regimens in a population with limited treatment options, highlighting the therapy’s generally favorable safety profile and reinforcing the company’s positioning in the emerging field of localized-plus-systemic cancer treatment for head and neck malignancies.
The most recent analyst rating on (DRTS) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral.
The score is held back primarily by very weak financial performance (no revenue, widening losses, and accelerating cash burn), which increases funding and dilution risk. Technicals are more constructive on a longer-term basis (above 50/100/200-day averages with neutral momentum), but valuation is limited by negative earnings and no dividend support.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company focused on the research, development and potential commercialization of Alpha DaRT, a diffusing alpha-emitters radiation therapy for solid tumors. The company’s lead technology delivers highly localized intratumoral alpha radiation intended to destroy tumors while sparing surrounding healthy tissue, and has been studied in the United States, Europe, Israel and Japan.
Average Trading Volume: 317,837
Technical Sentiment Signal: Buy
Current Market Cap: $662.7M
See more data about DRTS stock on TipRanks’ Stock Analysis page.